The Severe Acute Respiratory Syndrome Coronavirus 3a Protein Up-Regulates Expression of Fibrinogen in Lung Epithelial Cells by Tan, Yee-Joo et al.
JOURNAL OF VIROLOGY, Aug. 2005, p. 10083–10087 Vol. 79, No. 15
0022-538X/05/$08.000 doi:10.1128/JVI.79.15.10083–10087.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
The Severe Acute Respiratory Syndrome Coronavirus 3a Protein
Up-Regulates Expression of Fibrinogen in Lung
Epithelial Cells
Yee-Joo Tan,* Puay-Yoke Tham, Daphne Z. L. Chan, Chih-Fong Chou, Shuo Shen,
Burtram C. Fielding, Timothy H. P. Tan, Seng Gee Lim, and Wanjin Hong
Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, Singapore 138673
Received 20 March 2005/Accepted 18 April 2005
Here we analyzed the gene expression profile of cells that stably express the severe acute respiratory
syndrome coronavirus (SARS-CoV) 3a protein to determine its effects on host functions. A lung epithelial
cell-line, A549, was chosen for this study because the lung is the primary organ infected by SARS-CoV and
fatalities resulted mainly from pulmonary complications. Our results showed that the expression of 3a
up-regulates the mRNA levels of all three subunits, A, B, and , of fibrinogen. Consequently, the intracel-
lular levels as well as the secretion of fibrinogen were increased. We also observed increased fibrinogen levels
in SARS-CoV-infected Vero E6 cells.
A novel coronavirus was identified as the etiological agent
for the recent severe acute respiratory syndrome (SARS) ep-
idemic (5). Besides the replicase 1a/1b gene and the major
structural proteins, the SARS coronavirus (CoV) genome con-
tains open reading frames with no homologues in other coro-
naviruses (16, 21, 30). One of these is the 3a protein, which has
been detected in SARS-CoV-infected cells and virions (12, 24,
29, 36, 37).
To understand the role of 3a during SARS-CoV infection,
A549, a lung cell line with properties of type II epithelium (15),
was transfected with plasmid pXJ40neo-3a as previously de-
scribed (28). The 3a gene was obtained from isolate SIN2774
(29) and cloned into the pXJ40neo vector (38). Cells stably
expressing 3a were obtained after antibiotic selection as pre-
viously described (27) and the expression of 3a in two inde-
pendent clones (U1 and U2) was analyzed by Western blot
analysis (Fig. 1A) using a specific antibody (29). Control cells
were stably transfected with an empty vector.
An oligonucleotide microarray analysis was performed to
determine changes in the mRNA levels of host proteins. Total
RNA was extracted from these cells using the RNeasy kit
(QIAGEN) and hybridized to the HGU133A array, which
contains 22,000 human transcripts, according to standard
protocols available from Affymetrix. The results showed that
all three subunits, A, B, and , of fibrinogen (Table 1) were
strongly up-regulated in the 3a-expressing clones. Compared
to control cells, the mRNA levels of these genes increased by
26- to 294-fold. The increases in the mRNA levels of the
fibrinogen genes were verified independently by reverse tran-
scription-PCR (Fig. 1B) as previously described (26).
The only other fibrinogen-related gene that showed an in-
crease in the mRNA level in the 3a-expressing clones was Fgl-1
(Table 1, Fig. 1B), but the degree of up-regulation was less.
Fgl-1 belongs to the fibrinogen superfamily and contains do-
mains homologous to fibrinogen B and  proteins (35). All
other genes that were up-regulated by at least eightfold are
shown in Table 1. Twenty-four transcripts, representing 0.11%
of the total transcripts analyzed, were up-regulated in the 3a-
expressing cells suggesting that 3a did not cause massive
changes to the host gene profile. Interestingly, the mRNA level
of CSPG2, which is involved in the extracellular matrix assem-
bly (32), was also specifically up-regulated, with four different
transcripts giving similar results (Table 1). The significance of
the changes in these genes will need further evaluation.
The fibrinogen subunits are assembled to form the circulat-
ing 340-kDa fibrinogen complex, which consists of two units of
each of the subunits linked by disulfide bonds (1, 9, 20). Under
reducing conditions, the complex dissociates into the three
subunits with expected molecular weights of 66,000 (A),
52,000 (B), and 46,000 (). To determine the intracellular
levels of fibrinogen, cells were harvested and lysed in Laemmli’s
sodium dodecyl sulfate buffer (containing 200 mM dithiothre-
itol), then heated at 100°C, and subjected to Western blot
analysis using monoclonal antibodies (Accurate Chemical and
Scientific Corporation) against the A, B, and  fibrinogen
subunits. Human plasma and serum (Sigma) were used to test
the specificity of the antibodies.
Monoclonal antibody against the A subunit detected a ma-
jor protein of 75 kDa in the human plasma and two proteins
of 75 kDa and 70 kDa in Huh7 cells (Japan Health Sci-
ences Foundation), a liver cell line that constitutively expresses
fibrinogen (Fig. 2A, panel b, lane 3). Consistent with the in-
crease in the mRNA, the A protein levels in the 3a-expressing
clones were significantly higher than in the vector control (Fig.
2A, panel b, lanes 4 to 6). In contrast to Huh7 cells, only the
75-kDa protein was detected in clones U1 and U2 (Fig. 2A,
panel b, lanes 3, 5, and 6). It is unclear why two forms of A
were detected in Huh7 cells, but differences in the processing
of fibrinogen in exhepatic and hepatic cells have been reported
(22).
As shown in Fig. 2A, the B subunit in the plasma and Huh7
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cells migrated at 64 kDa (panel c, lane 3). As for the 
subunit, the protein in the plasma migrated at60 kDa but the
protein in Huh7 cells migrated at only 45 kDa, suggesting
that the intracellular  polypeptide underwent some form of
posttranslational modifications before secretion into the extra-
cellular matrix (panel a, lane 3). Consistently, the levels of both
B and  proteins in the 3a-expressing clones were also higher
than that in the vector control (Fig. 2A, panels c and a, lanes
4 to 6).
To determine the secretion of fibrinogen, 106 cells were
resuspended in 1.5 ml of Opti-MEM (Invitrogen). After 24 h,
the amounts of fibrinogen and interleukin-6 present in the
culture supernatants were determined using the ZYMUTEST
Fibrinogen enzyme-linked immunosorbent assay (ELISA)
(Hyphen BioMed) and the human interleukin-6 Quantikine
ELISA (R&D systems), respectively. Concurrently, the cell
numbers were counted using a hemacytometer and used to
compute the amount of fibrinogen secreted per cell. All exper-
FIG. 1. Stable expression of SARS-CoV 3a in A549, a lung epithe-
lial cell line, and effects on the mRNA levels of fibrinogen A, B, and
 subunits and fibrinogen-related proteins. (A) Western analysis show-
ing the expression of 3a in the stable cell lines clones U1 and U2 but
not in the vector control (VEC) cells (top panel). An unknown cellular
protein cross-reacting with the anti-3a mouse polyclonal is marked
with an asterisk. Equal amounts of cells were used in each lane as
verified by the level of endogenous actin (bottom panel). (B) Reverse
transcription-PCR results showing the higher mRNA levels of fibrin-
ogen subunits A, B, and  in clones U1 and U2 compared to the
vector control. The mRNA level of fibrinogen-like 1, a member of the
fibrinogen superfamily, was also increased in the presence of 3a. The
primers used (5 to 3) were A1: TCACTGAATCTAACCATAGCT
GACC (sense) and A2: AAGGCAAGACCACCAGGATTAAAGA
(antisense) for probe set ID205649_s_at; A3: TTCGACACTGCCTC
AACTGGAAAAA (sense) and A4: GGGCGAGATTTAGCATGGC
CTCTCT (antisense) for probe set ID205650_s_at; B1: GTCATGCA
GCCAATCCAAACGGCAG (sense) and B2: CGACAAGGATAAA
AGACCCCTCTTC (antisense) for probe set ID204988_at; B3: GGT
CATCGACCCCTTGACAAGAAGA (sense) and B4: GCATGGGG
TGCGACAATATTCCATT (antisense) for probe set ID216238_s_at;
G1: CTTCGCTGGTGGGGATGCTGGAGAT (sense) and G2: CAT
AACCATTAGGAGTAGATGCTTT (antisense) for probe set
ID219612_s_at; and L1: CAGCTGGAGATTCCCTTGCGGGGAA
(sense) and L2: ATTAAGTAACAAAGGCAAGTGAGAA (anti-
sense) for probe set ID205305_at. The level of glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) mRNA was used to verify that equal
amounts of RNA were used in each reaction, and the primers used
were GAPDHfor: CTGAGAACGGGAAGCTTGTCATCA (sense)
and GAPDHrev: CGTCTAGCTCAGGGATGACCTTG (antisense).
TABLE 1. Increase in the mRNA levels of fibrinogen and
fibrinogen-related genes, as well as other cellular genes, in 3a-
expressing stable A549 cell lines, clones U1 and U2, as determined
by oligonucleotide microarray analysis
Accession no.
(gene symbol)
Probe set
IDa Description
Fold
increaseb
U1 U2
NM_000508.2 (FGA) 205649_s_at Fibrinogen, A 294 181
205650_s_at Fibrinogen, A 60 26
NM_005141.1 (FGB) 204988_at Fibrinogen, B 181 74
216238_s_at Fibrinogen, B 79 32
NM_000509.3 (FGG) 219612_s_at Fibrinogen,  158 60
NM_004467.1 (FGL1) 205305_at Fibrinogen-like 1 15 10
NM_004385.1 (CSPG2) 204620_s_at Chondroitin sulfate
proteoglycan 2 (ver-
sican)
17 16
221731_x_at Chondroitin sulfate
proteoglycan 2 (ver-
sican)
24 21
211571_s_at Chondroitin sulfate
proteoglycan 2 (ver-
sican)
21 21
215646_s_at Chondroitin sulfate
proteoglycan 2 (ver-
sican)
21 20
NM_001680.2 (FXYD2) 205674_x_at FXYD domain con-
taining ion transport
regulator 2
26 32
207434_s_at FXYD domain con-
taining ion transport
regulator 2
17 26
NM_002937.1 (RNASE4) 205158_at Ribonuclease, RNase
A family 4
14 13
213397_x_at Ribonuclease, RNase
A family 4
21 18
NM_003982.1 (SLC7A7) 204588_s_at Solute carrier family 7
(cationic amino acid
transporter, y sys-
tem)
24 30
AB002155.1 (UPK1B) 210065_s_at Uroplakin 1B 18 21
BC001386.1 (TM4SF4) 209937_at Transmembrane 4 su-
perfamily, member 4
11 26
NM_024795.1 (FLJ22800) 220639_at Hypothetical protein
FLJ22800
26 26
U80736.1 (TNRC9) 215108_x_at Trinucleotide repeat
containing 9
74 119
NM_014059.1 (RGC32) 218723_s_at Response gene to
complement 32
28 42
NM_005980.1 (S100P) 204351_at S100 calcium binding
protein P
15 11
AF088867.1 (AGR2) 209173_at Anterior gradient 2
homolog (Xenopus
laevis)
23 23
NM_004915.2 (ABCG1) 204567_s_at ATP-binding cassette,
subfamily G
(WHITE), member 1
18 15
NM_000187.1 (HGD) 205221_at Homogentisate 1,2-
dioxygenase (ho-
mogentisate oxi-
dase)
12 10
a Probe set ID refers to the identification given to each transcript on the
Affymetrix array, and details on each transcript are available at https://www.af-
fymetrix.com.
b Only genes that showed at least an eightfold increase compared to a vector
control clone in both clones were selected. A comparison was also made between
two independent vector control clones to ensure that none of these up-regulated
genes showed significant variance in basal mRNA levels.
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iments were performed in duplicate, and quantifications were
performed according to the manufacturer’s protocol. As shown
in Fig. 2B, high levels of fibrinogen (30 ng per 106 cells) were
secreted from the 3a-expressing clones.
Previously, interleukin-6 was found to synergize with dexa-
methasone to increase the fibrinogen levels (6, 25). However,
no significant increase in interleukin-6 was detected in culture
supernatant from the 3a-expressing clones (data not shown),
suggesting that this process may be independent of proinflam-
matory cytokines. No change in the mRNA of cytokine-related
genes was observed in the microarray analysis, although we
cannot rule out that there may be changes at the protein level.
As A549 cells do not support SARS-CoV replication (8), the
intracellular level of fibrinogen  (and secretion of fibrinogen)
in SARS-CoV-infected Vero E6 cells was determined. Infec-
tion was carried out as previously described (24). The expres-
sion of fibrinogen  was higher in infected cells than mock-
infected cells (Fig. 3A). Similarly, Vero E6 transiently
transfected with a 3a cDNA construct also showed a higher
level of fibrinogen  than mock-transfected cells (Fig. 3A). The
monoclonal antibodies against A and B could not recognize
these proteins in Vero E6 (derived from African green mon-
key), probably due to species differences (data not shown). The
FIG. 2. Effects of SARS-CoV 3a protein on the intracellular level
of fibrinogen subunits and the secretion of fibrinogen complex into
culture supernatant. (A) Western blot analysis with specific monoclo-
nal antibodies was used to detect the A, B, and  subunits of
fibrinogen in human plasma (lane 1) and Huh7 cells (lane 3), a human
liver cell line that constitutively expresses fibrinogen. Lane 2 was
loaded with a similar amount of human serum as a negative control
and for all three antibodies did not cross-react with proteins present in
human serum. The intracellular levels of the A, B, and  subunits of
fibrinogen were higher in the 3a-expressing clones (U1 and U2) com-
pared to the vector control cells (VEC) (panels a to c). Equal loadings
of cell lysates was verified by the level of endogenous actin (panel d).
(B) The amounts of fibrinogen secreted into the cell culture superna-
tants, as determined by an ELISA, were higher for the 3a-expressing
stable clones U1 and U2 compared to the vector control cells (VEC)
(columns 2 to 4). The amount of fibrinogen secreted by Huh7 cells was
also determined (column 1). This experiment was repeated three
times, and similar results were obtained each time. A representative
set of data (mean  standard deviation) is presented.
FIG. 3. Changes in the intracellular level of fibrinogen  subunit
and secretion of fibrinogen complex into culture supernatant of Vero
E6 cells infected with SARS-CoV. (A) Mock- and SARS-CoV-infected
Vero E6 cells (lanes 1 and 2, respectively) were subjected to Western
blot analysis with the anti-3a polyclonal to determine the expression
level of 3a (first panel). Vero E6 cells transiently expressing 3a or a
control protein, hemagglutinin (HA)-glutathione S-transferase (GST),
was similarly analyzed (lanes 3 and 4, first panel). Since the anti-3a
antibody was obtained using a GST fusion protein, it recognizes both
the 3a and GST proteins. Monoclonal antibody against fibrinogen 
subunit was used to determine the intracellular level of this protein
(second panel). The level of endogenous tubulin was used to compare
the amount of total cell lysates used (third panel). (B) The amount of
fibrinogen secreted by mock- and SARS-CoV-infected cells into the
cell culture supernatants was determined using an ELISA for measur-
ing human fibrinogen. Vero E6 cells were infected at a multiplicity of
infection of 0.1 for 2 h and then replaced with the unsupplemented
medium. At approximately 14 h postinfection, the cells showed ap-
proximately 50% cytopathic effect, and the culture supernatants were
collected. Determination of the exact concentration of fibrinogen se-
creted by Vero E6 cells was not possible as no standard for fibrinogen
from African green monkeys was available. Two independent infection
experiments were performed, and for each sample, two readings were
obtained, and the data were subjected to paired two-sample Student t
tests for means (Excel, Microsoft) to determine if the difference in
fibrinogen secreted from mock- and SARS-CoV-infected cells was
significant (n  4, two-tailed, P  0.003). Data represent mean 
standard deviation. The absorbance readings for human fibrinogen
standards are shown for comparison.
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level of fibrinogen in the culture supernatant from infected
Vero E6 cells was also significantly higher than that from
mock-infected cells (Fig. 3B, P 	 0.005), but we could not
determine the concentration, as the assay was designed for
measuring human fibrinogen and no standard from the African
green monkeys was available.
Coincidently, up-regulation of fibrinogen mRNA was also
observed in peripheral blood mononuclear cells infected by
SARS-CoV in vitro (17). During an acute-phase response to
infection, injury, or neoplasia, the production of fibrinogen by
the liver increases to restore homeostasis (1, 3, 4, 9). Increased
production of fibrinogen at exhepatic tissues, as in the lung (13,
23), also helps in this process. However, the excessive produc-
tion of fibrinogen and formation of fibrin at the site of injury
may enhance cytokines production or imbalance procoagulant
and/or fibrinolytic activities (11, 31).
Postmortem examinations of SARS victims revealed exten-
sive lung damage that is typical of acute respiratory distress
syndrome (2, 7, 10, 18). In addition, most SARS patients have
thrombocytopenia, elevated D-dimers, and prolonged acti-
vated partial thromboplastin time, which suggest dysregulation
of the coagulation and fibrin polymerization pathways (14, 19,
33, 34). Taken together with the fibrinogen up-regulation in
both infected peripheral blood mononuclear cells and Vero E6
cells (reference 17 and data therein), it seems that increased
fibrinogen expression and fibrin degradation products could
play an important role in SARS pathogenesis. Our data also
demonstrated that expression of 3a alone can up-regulate the
expression of fibrinogen, suggesting that 3a may contribute to
SARS pathogenesis.
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